Acute myeloid leukemia (AML) is a heterogeneous disease increasing in frequency owing to an aging population. Decisions on intensive induction treatments, intensification and allografting rely on the ability to divide an apparently homogeneous group according to risk. A wide range of clinical, cytogenetic and molecular variables may be used to inform this task; here we examine those variables useful in assessing prognosis for a patient with non-acute promyelocitic AML focusing on core binding factor leukemia. In clinical practice, when counseling an individual patient with AML, a range of well-known clinical variables (age, performance status and tumor burden) and genetic variables (cytogenetic and gene mutation) must be considered to better define the prognostic risk.

急性髓性白血病 (AML) 是一种异质性疾病，由于人口老龄化而频率增加。关于强化诱导治疗、强化和同种异体移植的决定依赖于根据风险划分明显同质组的能力。广泛的临床、细胞遗传学和分子变量可用于为这项任务提供信息；在这里，我们检查了那些可用于评估非急性早幼粒细胞 AML 患者预后的变量，重点是核心结合因子白血病。在临床实践中，当咨询个体 AML 患者时，必须考虑一系列众所周知的临床变量（年龄、体能状态和肿瘤负荷）和遗传变量（细胞遗传学和基因突变），以更好地确定预后风险。